Business Context and Reporting Period
This Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on January 13, 2020. The report discloses the entry into a material definitive agreement regarding a new lease for principal executive offices and research and development laboratories.
Key Financial Metrics and Lease Terms
- Property: Approximately 61,307 square feet at 75 Hayden Avenue, Lexington, Massachusetts.
- Lease Term: Initial term of 10 years, expected to commence December 1, 2020, and end April 30, 2031.
- Base Rent: Approximately $4.08 million for the first year, increasing at 3% annually thereafter.
- Tenant Improvement Allowance: Up to $11.03 million from the landlord, plus an optional additional allowance of up to $0.9 million.
- Security Deposit: $1.7 million required in the form of a letter of credit.
- Additional Costs: Company responsible for its share of operating expenses, taxes, and utilities.
Material Changes
The filing represents a material change in the company's operational footprint, transitioning to a new facility to support research and development activities. The filing text does not provide comparative financial data or changes versus prior periods as this is a current event report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
The company intends to use the new premises as its principal executive offices and laboratory. The lease includes options to extend the term for two additional five-year periods and to sublet the premises. A material risk noted is that in the event of a default on certain obligations, the landlord retains the right to terminate the lease and recover damages. The filing text does not provide specific guidance on future revenue, profit, or cash flow projections.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Frequency Therapeutics, Inc., not Korro Bio, Inc.
- Confirm the impact of the $1.7 million letter of credit requirement on current liquidity.
- Review the full lease agreement (to be filed as an exhibit to the 2019 Form 10-K) for detailed covenants and termination clauses.
- Assess the timeline for the December 2020 commencement date and potential delays.